Henna Hand Design

Henna Hand Design

Virtual Reality Devices for Home use

 Facebook's virtual reality push is about data, not gaming

Marcus Carter, University of Sydney and Ben Egliston, Queensland University of Technology

Facebook has announced the latest version of its successful standalone virtual reality (VR) headset, the Oculus Quest 2. The new device packs more computing power and a sharper screen than its predecessor, and is also US$100 cheaper.

Facebook’s Oculus Quest 2 (from AUD$479) is a powerful wireless VR headset for gaming and, Facebook hopes, much more.

The Oculus Quest 2 is the latest step in Facebook’s long-term strategy of making VR more accessible and popular. Facebook recently brought all its VR work under the umbrella of Facebook Reality Labs, it has announced new applications like the Infinite Office VR workplace, and will also require a Facebook login for future Oculus devices.

The compulsory link to Facebook has many consumers concerned, considering the social media giant’s chequered history with privacy and data. VR and its cousin, augmented reality (AR), are perhaps the most data-extractive digital sensors we’re likely to invite into our homes in the next decade.

Why does Facebook make virtual reality headsets?

Facebook acquired VR company Oculus in 2014 for an estimated US$2.3 billion. But where Oculus originally aimed at gamers, Facebook boss Mark Zuckerberg wants VR for social media.

At the same event last year, Zuckerberg said Facebook sees VR as a pathway to a new kind of “social computing platform” using the enhanced feeling of “presence” that VR affords. For Facebook, the introduction of VR-based computing will be like the leap from text-based command line interfaces to the graphical user interfaces we use today.

This may well be right. VR affords a strong feeling of embodied presence that offers new possibilities for entertainment, training, learning and connecting with others at a distance.

But if the VR future is the one Facebook is “working in the lab” on, it will function via the company’s existing social computing platform and business model of extracting data to deliver targeted advertisements.

Virtual reality collects real data

A VR headset collects data about the user, but also about the outside world. This is one of the key ethical issues of emerging “mixed reality” technologies.

As American VR researcher Jeremy Bailenson has written:

…commercial VR systems typically track body movements 90 times per second to display the scene appropriately, and high-end systems record 18 types of movements across the head and hands. Consequently, spending 20 minutes in a VR simulation leaves just under 2 million unique recordings of body language.

The way you move your body can be used to identify you, like a fingerprint, so everything you do in VR could be traced back to your individual identity.

Facebook’s Oculus Quest headsets also use outward-facing cameras to track and map their surroundings.

Facebook VR headsets use Simultaneous Localisation and Mapping (SLAM) to track the movements of the headset in 3D space. This is also another opportunity for collecting data about the world.

In late 2019 Facebook said they “don’t collect and store images or 3D maps of your environment on our servers today”. Note the word today, which tech journalist Ben Lang notes makes clear the company is not ruling out anything in the future.

Virtual reality leads to augmented reality

Facebook wants to collect this data to facilitate its plans for augmented reality (AR).

Where VR takes a user to a fully virtual environment, AR combines virtual elements with our real surroundings.

Last year Facebook unveiled the Live Maps application, a vision of an expansive surveillance apparatus presumably powered by AR glasses and data collected from Oculus Insight. Live Maps will provide many minor conveniences for Facebook users, like letting you know you’ve left your keys on the coffee table.

Facebook’s Live Maps application is a vision of a Facebook owned AR platform.

Now Facebook have announced their first steps towards making this a reality: Project Aria. This will involve people wearing glasses-like sensors around Seattle and the San Francisco Bay area, to collect the data to build what Wired co-founder Kevin Kelly calls “the mirrorworld”, the next big tech platform.


Read more: Pokémon Go wants to make 3D scans of the whole world for 'planet-scale augmented reality experiences'. Is that good?


People are rightly concerned about the ethical implications of this kind of data extraction. Alongside Project Aria, Facebook launched its Responsible Innovation Principles page, and they’re already quick to emphasise that faces and license plates will be blurred in this data collection.

As we have argued elsewhere, framing questions about VR and AR surveillance in terms of individual privacy suits companies like Facebook very well. That’s because their previous failings are actually in the (un)ethical use of data (as in the case of Cambridge Analytica) and their asymmetric platform power.


Read more: Why the business model of social media giants like Facebook is incompatible with human rights


We need more than just ‘tech ethics’

Groups like the XR Safety Initiative recognise these emerging issues, and are beginning work on standards, guidelines and privacy frameworks to shape VR and AR development.

Many emerging technologies encounter what is known as the Collingridge problem: it is hard to predict the various impacts of a technology until it is extensively developed and widely used, but by then it is almost impossible to control or change.

We see this playing out right now, in efforts to regulate Google and Facebook’s power over news media.

As David Watts argues, big tech designs its own rules of ethics to avoid scrutiny and accountability:

Feelgood, high-level data ethics principles are not fit for the purpose of regulating big tech … The harms linked to big tech can only be addressed by proper regulation.

What might regulation of Facebook’s VR look like? Germany offers one such response – their antitrust regulations have resulted in Facebook withdrawing the headset from sale. We can only hope the technology doesn’t become too entrenched to be changed, or challenged.

But regulation has not always stopped Facebook in the past, who paid out US$550 million to settle a lawsuit for breaching biometric privacy laws. In the multi-billion dollar world of big-tech, it’s all a cost of doing business.

Another question we might ask ourselves is whether Facebook’s virtual-reality future and others like it really need to exist. Maybe there are other ways to avoid forgetting your keys.The Conversation

Marcus Carter, Senior Lecturer in Digital Cultures, SOAR Fellow., University of Sydney and Ben Egliston, Postdoctoral research fellow, Digital Media Research Centre, Queensland University of Technology

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Masquerade Masks

Masquerade Masks



Kitchen Appliance Deals

Those who want to know where employment trends are going the best place to look is the global economy. The future of natural gas and alternative energy is causing many start-up companies to have to hire college graduates. Job creation can be seen in areas of medical breakthroughs and developments. So what are the highest paying undergraduate majors you ask. Well this article will cover those industries and why it is in your best interest to take notice. Unemployment is high and job creation is low, in this type of economic environment only those who can see the silver lining will succeed and get paid good money because of it. Education and the Workforce Going to college is a great idea if you pick a career that is in high demand among employers. One thing to remember is that many college graduates can not find work after school. The main reason is because although they have Bachelors Degree they did not choose the right majors. Studying undergraduate majors in association with salary data helps students plan out a career that will be beneficial for not only them but their families as well. Biology and life science will continue to outperform most industries due to the need for the development of curing diseases throughout the world. Math and computer science will prepare students for any type of employment and usually pays higher than social service and counseling degrees. The Gender Gap and Pay Range Recent reports have showcased how men make more money than women, now they were comparing salary based on education and career choice. New developments show that men choose higher earning majors in engineering and pharmaceutical sciences, while women end up in low paying majors such as education and social work. College Degrees and School Loans Considering the high cost of education it is best to look at how much money you will be paying back each year on your loans when you start working. Your lifetime earnings is what needs to be evaluated. Picking a career that does not pay well will only put you further in debt. Also if you pick an occupation with high unemployment statistics or lack of job creation you will not be able to continue living the lifestyle you want. Choose industries that have virtually no vacancies such as geological and geophysical engineering or military technologies. Also agricultural and natural resources will have plenty of jobs for graduates. Top 10 Highest Paying Majors Chemical Engineering Petroleum Engineering Aerospace Engineering Computer Engineering Electrical Engineering Applied Mathematics/Statistics Networking Systems Computer Science Information Technology Telecommunications As you can see the highest paid majors are also the hardest courses a student can take requiring dedication, commitment to learning. Most colleges will only accept students with high GPA in to these college degrees.

Telemedicine, or telehealth, companies

How To Find Public Domain Materials Online Public domain works is available on the web, it just take time to find it. The reason this type of content is so popular is because it basically can be used, reproduced and incorporated without restrictions.

As you are probably aware most published content such as music, software, books and photos have copyrights that require permission and usage grants. In the case of U.S. Government documents most are considered to be part of the public domain, unless otherwise stated. That is why it is important to consider what country the public domain material is coming from.

One thing you will find when you try to find public domain books through the search engines that some people are trying to sell the sources to you for a fee. I guess if you do not want to do the research yourself it may be worth the cost of admission, but on the other hand it is really not that hard to find the sources for free.

I like to research so for me it was a challenge to see if I could find anything and it turns out that if you know where to look you can find a treasure of free resources to use anyway you want to. Top Places to find Public Domain Resource Information Okay so lets get started.

Remember I am not an expert in this area and pretty much this is just my opinion on the subject. Also this article does not cover every aspect of the public domain intellectual property rights it is just an overview.

Websearch.about.com - this is a section written by Wendy Boswell an about.com guide and I will have to say that I think she is one of the best researchers on the web, basically she provides resources on how to find just about anything online. websearch.about.com/bio/Wendy-Boswell-13134.htm Wikipedia commons - has a large database of media files that have been contributed from a variety of sources for nature, science, society, images, sounds and videos. commons.

wikimedia.org/wiki/Main_Page Google Book Search - here you can find a library of scanned books, and many of the public domain books can be downloaded. Under the advanced book search link you want to enter the date of the books you want anything before the year 1923 will be part of the public domain.

books.google.com/advanced_book_search Project Gutenberg - is one of the oldest sources on the web with thousands of books that come in a variety of formats such as the Kindle and Sony Reader. gutenberg.org/wiki/Main_Page Questia - is one of my favorites because of the selection is not just books but it includes magazines, newspapers, journals in the humanities and social sciences. questia.com/library/encyclopedia Amazon Books - this is an untapped resource, if you go to the amazon store and under the books category type in public domain it will give you a list of helpful resources some are even free if you have a kindle reader.

amazon/public-domain The Mutopia Project - has free music downloads, All of the music on Mutopia may be freely downloaded, printed, copied, distributed, modified, performed and recorded.

mutopiaproject.org Public Domain Resource page:

 Here is a helpful guide of public domain resources provided by wikipedia, the list includes everything from Dictionaries, Mathematics, Historical, Language and Linguistics, Political science, Psychology, Architecture, Business and industry, Communication, Computer science, Education, U.S. federal government, Non-U.S. federal government, Solar energy, Law, Science, medicine, and technology, Classics, Music, and Religion.

en.wikipedia.org/wiki/Wikipedia:Public_domain_resources

It will be easier to find what your looking for if you put the exact phrase you want. For instance if you want images or photos then put that in the search box.

If you want books or literature than use that and if you want content from a specific genre such as "U.S. Government" or "public domain cookbooks" then make sure you are specific because otherwise you will get a general search and it will pull up things you don't want. I am sure if you look you can find tons more. Happy hunting!

Bailout Loans Cash for Equity


These 16 companies are working on treatments or vaccines


A mix of legacy drugmakers and small startups have stepped forward with plans to develop vaccines or treatments that target the infection caused by the novel coronavirus.
COVID-19, which was first detected in December in Wuhan, China, has sickened more than 370,000 people worldwide and killed at least 16,000. There are no Food and Drug Administration-approved vaccines or therapies for the disease.
In the U.S., many of the companies that are initiating development have received funding from two organizations: the Biomedical Advanced Research and Development Authority (BARDA), which is a division of the Department of Health and Human Services, and the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health. Some companies have also received funding from Coalition for Epidemic Preparedness Innovations (CEPI), a global organization based in Oslo. Other companies are funding trials by themselves or through partnerships with other life sciences companies.
Here are some of the companies developing treatments or vaccines in the U.S. for COVID-19:
Companies: BioNTech SE and Pfizer Inc.
Type: Vaccine
Stage: Preclinical
Name: BNT162
Background: On March 17, Pfizer announced that it would help develop and distribute BioNTech SE’s COVID-19 vaccine candidate, though the deal excludes China. BioNTech plans to put the vaccine candidate into clinical trials in late April, in Germany and the U.S. It is testing the vaccine in collaboration with Shanghai Fosun Pharmaceutical Group Co. Ltd. in China. Pfizer and BioNTech for several years have said they would partner to develop mRNA-based influenza vaccines.
Year-to-date stock performances: Shares of BioNTech have soared 104%; Pfizer’s stock is down 20%.

Company: Gilead Sciences Inc. US:GILD
Type: Treatment
Stage: Phase 3 clinical trials
Name: remdesivir
Background: Gilead is a longtime drugmaker best known for developing the first major cure for hepatitis-C in Sovaldi, a therapy that changed the standard of care for that disease but also kicked off the national debate about drug pricing. The company has experience developing and marketing HIV drugs, including Truvada for pre-exposure prophylaxis (PrEP), its preventive HIV medicine. Along with U.S. trials, Gilead is conducting a randomized, controlled clinical trial in Wuhan, testing remdesivir as a treatment for mild to moderate forms of pneumonia in people with the virus. The trial was given the go-ahead by China’s Food and Drug Administration in February.
Clinical trials:
1. On Feb. 21, the National Institute of Allergy and Infectious Diseases started enrolling patients in a randomized, double-blind, placebo-controlled Phase 2 trial evaluating 394 hospitalized patients with COVID-19 at up to 50 sites worldwide, including at three sites in Singapore and South Korea. However, the majority of the study locations are in the U.S. The trial is expected to conclude April 1, 2023. Sites include the National Institutes of Health in Bethesda, Md., (not recruiting), the University of Nebraska Medical Center in Omaha (recruiting), the University of Texas Medical Branch in Galveston (not recruiting), and Providence Sacred Heart Medical Center in Spokane (recruiting).
2. On March 3, Gilead said a randomized, open-label Phase 3 trial will evaluate remdesivir in 600 patients with moderate COVID-19. The trial start enrolling patients in March, with results to come in May. The clinical trial listing states the study is taking place in Hong Kong, Singapore, South Korea and the U.S.
3. On March 3, Gilead said a randomized, open-label Phase 3 trial will evaluate remdesivir in 400 patients with severe COVID-19. The trial start enrolling patients in March, with results in May. The clinical trial listing states the study is taking place in Hong Kong, Singapore, South Korea and the U.S.
Year-to-date stock performance: Shares of Gilead are up 13.4%.

Company: GlaxoSmithKline US:GSK
Type: Pandemic adjuvant platform for vaccines
Name: AS03 Adjuvant System
Background: GSK is another leading vaccine maker, having brought to market vaccines for human papillomavirus (HPV) and the seasonal flu, among others. On Feb. 3, it said the CEPI-funded University of Queensland will have access to the British drugmaker’s vaccine adjuvant platform technology, which is believed to both strengthen the response of a vaccine and limit the amount of vaccine needed per dose. On Feb. 24, GSK said that Clover Biopharmaceuticals Inc., a Chinese biotechnology company, is also using its adjuvant technology in combination with its vaccine candidate, COVID-19 S-Trimer, in preclinical studies. Dr. Thomas Breuer, chief medical officer for GSK Vaccines, is leading work on vaccines and the adjuvant platform.
Year-to-date stock performance: Shares of GSK have tumbled 23.5%.

Company: Heat Biologics Inc. US:HTBX
Type: Vaccine
Stage: Preclinical
Background: Heat Biologics has previously announced that it is developing a vaccine for the novel coronavirus with the University of Miami Miller School of Medicine. It disclosed March 17 in a financial filing that its COVID-19 vaccine candidate had been added to the World Health Organization’s “draft landscape” of 41 candidate vaccines. The company also recently joined the Alliance for Biosecurity, which may help it “secure government funding to support its rapid development, production, and distribution” of its COVID-19 vaccine, according to Maxim Group analysts.
Year-to-date stock performance: Heat’s stock has gained 19%.

Company: Inovio Pharmaceuticals Inc. US:INO
Type: DNA-based vaccine
Stage: Preclinical
Name: INO-4800
Background: Another CEPI grantee, awarded $9 million, Inovio has said it already began preclinical testing and small-scale manufacturing.
Timeline: Inovio develops immunotherapies and vaccines but hasn’t yet had a product approved for treatment. For INO-4800, preclinical testing was performed between Jan. 23 and Feb. 29. The company plans to begin clinical trials in the U.S. with 30 participants in April. It also plans to launch human trials in China and South Korea that same month, and says that it has a total of 3,000 doses prepared for the trials in the three countries. Inovio said it expects to have the first results from the trial in the fall and to have 1 million does of the vaccine ready for additional clinical trials or emergency use by the end of the year. Inovio on March 12 announced a $5 million grant from the Bill & Melinda Gates Foundation to test a delivery device for its vaccine candidate. RBC analyst Gregory Renza recently downgraded the stock to sector perform from outperform on valuation grounds and said he believed in the technology.
Year-to-date stock performance: Shares of Inovio have soared 124.6%.

Company: Johnson & Johnson US:JNJ
Type: Vaccine
Name: TBD (“We are still in the process of identifying a vaccine candidate, so no there is no name at this time,” a spokesman said March 4.)
Background: On Feb. 11, J&J said it is working with BARDA to test its vaccine candidate, with both organizations providing funding for research and development and the public-health organization funding the Phase 1 trials. Similar to GSK, J&J’s AdVac and PER. C6 technologies are used to improve the development process for a vaccine and were also used to develop J&J’s experimental Ebola vaccine. “We are also in discussions with other partners, that if we have a vaccine candidate with potential, we aim to make it accessible to China and other parts of the world,” Dr. Paul Stoffels, J&J’s chief scientific officer, said in a statement. On March 13, J&J said it started preclinical testing on multiple candidates in collaboration with Beth Israel Deaconess Medical Center in Boston, and it aims to have a vaccine candidate by the end of the month. J&J also said in February that it partnered with BARDA on a project that aims to screen existing antiviral medications, including experimental or approved therapies, that may be effective against COVID-19.
Timeline: The company aims to start a Phase 1 clinical trial by the end of 2020, “compared to the typical five to seven years it takes for this milestone in vaccine development,” Dr. Paul Stoffels, J&J’s chief scientific officer and leader of J&J’s global COVID-19 response, said March 2.
Year-to-date stock performance: Shares of J&J are down 7.5%.

Company: Moderna Inc. US:MRNA
Type: RNA-based vaccine
Stage: Phase 1
Name: mRNA-1273
Background: Moderna received funding from CEPI in January to develop an mRNA vaccine against COVID-19. On Feb. 24, it said it had shipped the first batch of mRNA-1273 to the NIAID for a Phase 1 clinical trial in the U.S.
Clinical trials: The first patient in the Phase 1 trial received a dose of the vaccine candidate on March 16. The study is expected to enroll 45 healthy adult patients, between the ages of 18 and 55 years old, in an open-label Phase I clinical trial to test mRNA-1273 as a vaccine for COVID-19. It’s expected to conclude June 1, 2021. Participants will be followed for one year. The trial will be conducted at Kaiser Permanente Washington Health Research Institute in Seattle. CEPI funded the manufacturing of the investigational vaccine for the first phase of the trial, which is evaluating different doses for safety and immune response.
Year-to-date stock performance: Moderna’s shares have gained 51.4%.

Company: Novavax Inc. US:NVAX
Type: vaccines
Phase: preclinical
Background: Novavax, a preclinical biotechnology company, announced Feb. 26 it had several vaccine candidates in preclinical animal studies, and that it plans to initiate a Phase I clinical study by June. In March the company it had received $4 million from CEPI to develop a COVID-19 vaccine and that Emergent BioSolutions Inc. US:EBS would support contract development and manufacturing for the experimental vaccine.  
Year-to-date stock performance: Its stock has gained 165.6%.

Company: Regeneron Pharmaceuticals Inc. US:REGN
Type: Treatment
Stage: Preclinical
Name: No name yet
Background: On Feb. 4, Regeneron announced it is working on developing monoclonal antibodies as treatments for COVID-19. The company’s VelocImmune platform uses genetically-engineered mice with humanized immune systems in preclinical testing. “We are aiming to have hundreds of thousands of prophylactic doses ready for human testing by end of August,” a spokesperson said. Christos Kyratsous, VP of infectious disease R&D and viral vector technology, is running the project.
Year-to-date stock performance: Regeneron’s shares are up 29.8%.

Companies: Regeneron Pharmaceuticals and Sanofi
Type: Treatment
Stage: Phase 2/3 clinical trial
Name: Kevzara
Background: The FDA previously approved Kevzara, a treatment developed by Regeneron and Sanofi, as a therapy for rheumatoid arthritis in 2017.
Clinical trials:On March 16, the companies said they had started a Phase 2/3 trial testing Kevzara as a treatment for patients who have been hospitalized with severe COVID-19 infections. This randomized, double-blind, placebo-controlled trial is expected to enroll up to 400 patients and will take place at 16 sites in the U.S. New York’s Mount Sinai Hospital, the first site, has started enrolling patients, according to a company spokesperson. The aim is to evaluate if the drug lessens patient fevers and their need for supplemental oxygen. The Phase 3 trial will evaluate if Kevzara prevents deaths and reduces need for mechanical ventilation, supplemental oxygen, or hospitalization. Early results from a small 21-person trial in China that have not been peer-reviewed found that COVID-19 patients reported reductions in fever and 7% of them had a reduced need for supplemental oxygen within days of starting treatment.

Company: Roche Holding AG CH:ROG
Type: Treatment
Stage: Phase 3
Name: Actemra
Background: Roche’s Actemra was first approved in 2010 as a rheumatoid arthritis drug. The Swiss drugmaker has initiated a Phase 3 clinical trial evaluating Actera as a treatment for patients with COVID-19 who have been hospitalized with severe pneumonia. Roche expects to begin enrolling around 330 patients in early April, in the U.S. and elsewhere in the world. The company plans to examine patient mortality and need for mechanical ventilation or an intensive care unit stay among other primary and secondary endpoints. The trial is in partnership with BARDA.
Year-to-date stock performance: Roche’s stock is down 12%.

­
Company: Sanofi US:SNY
Type: Vaccine
Stage: Preclinical
Name: No name yet
Background: Starting Feb. 18, Sanofi is working with BARDA to test a preclinical vaccine candidate for severe acute respiratory syndrome (SARS) for COVID-19 using its recombinant DNA platform. It has a long history of producing vaccines in its Sanofi Pasteur business and acquired this candidate through its 2017 acquisition of Protein Sciences for $750 million. The French drugmaker previously worked with the organization on flu vaccines. Scientists in Meriden, Ct., are working on the vaccine; David Loew, Sanofi Pasteur’s EVP, is leading the project.
Timeline: A spokesperson said Sanofi aims to put a vaccine into a Phase 1 clinical trial between March 2021 and August 2021.
Year-to-date stock performance: Shares of Sanofi are down 14.4%.

Company: Takeda Pharmaceutical Company Ltd. US:TAK
Type: Treatment
Stage: Preclinical
Name: TAK-888
Background: The Japanese drugmaker said March 4 it plans to test hyperimmune globulins for people who are at high risk for infection. As part of its research, which will be performed in Georgia, Takeda said it would need access to plasma from people who have recovered from COVID-19 or those who have received a vaccine if one is developed. Dr. Rajeev Venkayya, president of Takeda’s vaccine business, is the co-lead of the company’s COVID-19 response team. Like J&J, Takeda plans to examine whether other therapies, both experimental or with regulatory approval, may have treatment potential.
Year-to-date stock performance: Shares of Takeda are down 29.0%.

Company: Vaxart Inc. US:VXRT
Type: Vaccine
Stage: Preclinical
Background:Vaxart was one of the first companies to announce plans to develop a vaccine when it did so Jan. 31. In March the clinical-stage company announced that Emergent BioSolutions will help develop and manufacture its oral vaccine candidate. “We believe an oral vaccine administered using a room temperature-stable tablet may offer enormous logistical advantages in the roll-out of a large vaccination campaign,” Vaxart CEO Wouter Latour said in a March 18 news release. The company plans to start a Phase 1 clinical trial in the U.S. in the second half of 2020, a company executive said.
Year-to-date stock performance: Vaxart’s stock is up 516.3%.
Company: Vir Biotechnology Inc. US:VIR and Biogen Inc. US:BIIB
Type: Treatment
Stage: Preclinical
Background: Vir said Feb. 25 it is collaborating with Shanghai-based WuXi Biologics to test monoclonal antibodies as a treatment for COVID-19. If the treatment is approved, WuXi will commercialize it in China, while Vir will have marketing rights for the rest of the world. The preclinical company is run by George Scangos, the former CEO of Biogen. It later announced a partnership with Biogen to help develop and manufacture its monoclonal antibodies as a potential treatment for COVID-19. Biogen will handle clinical manufacturing of Vir’s antibodies, the company said.
Year-to-date stock performance: Vir shares have jumped 324.9%; Biogen’s stock is up 4.9%.